vTv Therapeutics (VTVT) Cut to Hold at Zacks Investment Research

Zacks Investment Research cut shares of vTv Therapeutics (NASDAQ:VTVT) from a buy rating to a hold rating in a research report released on Saturday. They currently have $2.75 target price on the biotechnology company’s stock.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

vTv Therapeutics stock traded down $0.04 during trading hours on Friday, reaching $2.67. The stock had a trading volume of 1,180,413 shares, compared to its average volume of 5,511,327. vTv Therapeutics has a 52 week low of $0.65 and a 52 week high of $8.40.

vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.06. The firm had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.06 million. On average, sell-side analysts anticipate that vTv Therapeutics will post -0.73 EPS for the current year.

In other news, major shareholder Ronald O. Perelman bought 815,217 shares of vTv Therapeutics stock in a transaction on Thursday, December 27th. The stock was acquired at an average cost of $1.84 per share, for a total transaction of $1,499,999.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Ronald O. Perelman bought 1,879,700 shares of vTv Therapeutics stock in a transaction on Thursday, November 29th. The stock was purchased at an average price of $1.33 per share, with a total value of $2,500,001.00. The disclosure for this purchase can be found here. Insiders acquired 5,389,833 shares of company stock valued at $7,999,999 over the last quarter. 2.00% of the stock is currently owned by corporate insiders.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

See Also: Why do companies engage in swaps?

Get a free copy of the Zacks research report on vTv Therapeutics (VTVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit